Interleukin’s product development is focused on the fact that certain genetic variations among individuals produce life-long differences in a person’s disease progression depending on lifestyle and environment. Interleukin’s proprietary genetic technology helps to identify individuals who have a life-long tendency to over or under-express key chemicals in the body that lead to more disease or physical differentiation as they age. Individuals with these genetic differences also respond differently to certain treatments, diets, exercise or medication.
Our approach to test development is to create products that will benefit individuals seeking guidance for their particular conditions or illnesses. A genetic test must therefore be useful, understandable, and credible and serve as guidance for future action. The action resulting from the information provided by our genetic tests could be either some form of medical treatment, lifestyle change, or more careful monitoring of the person’s condition. It is important that a thorough understanding of the market potential for a potential genetic test be well understood prior to initiation of any research. Finally the company must be able to launch and sell a given product effectively.
One of the many benefits from the sequencing of the human genome is a new understanding of the role of genetic variations, such as single nucleotide polymorphisms (SNP) and haplotypes. Once used as a tool to help scientists decipher the human genome, SNP and haplotype analysis now is an important tool used to study the relevance of genetic variations to human health. A common SNP may cause a gene to make a different amount of a protein, change the timing of protein synthesis or make a variant protein, each of which may lead to a discernible physiological impact. We have focused on the SNP variations associated with inflammation and metabolic disease. Interleukin is using these genetic variations to actively develop an osteoarthritis risk test. Evaluations of additional new product lines is ongoing with the expansion of the pipeline of potential products in development.